CD69 and neoplasm: Additionally, our findings highlight that FLOT and CROSS regimens upregulate CD69 expression on T cells, which despite being an early marker of T cell activation also plays an important role in driving T cell exhaustion and may represent an attractive therapeutic target that could be combined with FLOT and CROSS regimens to enhance anti-tumour immunity, prevent immune exhaustion and ultimately promote tumour eradication in OGJ patients.